NEFH

Chr 22

neurofilament heavy chain

Also known as: CMT2CC, NFH

Neurofilaments are type IV intermediate filament heteropolymers composed of light, medium, and heavy chains. Neurofilaments comprise the axoskeleton and functionally maintain neuronal caliber. They may also play a role in intracellular transport to axons and dendrites. This gene encodes the heavy neurofilament protein. This protein is commonly used as a biomarker of neuronal damage and susceptibility to amyotrophic lateral sclerosis (ALS) has been associated with mutations in this gene. [provided by RefSeq, Oct 2008]

ResearchGenerating clinical summary…
MultiplemechanismLOEUF 1.06
Clinical SummaryNEFH
🧬
Gene-Disease Validity (ClinGen)
amyotrophic lateral sclerosis · ADLimited

Limited evidence — not for standalone diagnostic reporting

2 total gene-disease associations curated

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
9 unique Pathogenic / Likely Pathogenic· 658 VUS of 1122 total submissions
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
1.06LOEUF
pLI 0.000
Z-score 1.28
OE 0.75 (0.531.06)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?
0.52Z-score
OE missense 0.93 (0.871.01)
470 obs / 503.0 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.75 (0.531.06)
00.351.4
Missense OE?0.93 (0.871.01)
00.61.4
Synonymous OE?1.05
01.21.6
LoF obs/exp: 22 / 29.5Missense obs/exp: 470 / 503.0Syn Z: -0.52

This gene — mechanism propensity

DN
0.7130th %ile
GOF
0.6346th %ile
LOF
0.4332th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative, gain-of-function and loss-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOF1 literature citation
LOF100% of P/LP variants are LoF

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

GOFThe transfected cells appeared round and had significantly decreased axon-like projections compared to wildtype, and the aggregates trapped NEFL (162280), kinesin, and other proteins, and thus disrupted the neurofilament network in a toxic gain-of-function manner.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 27040688

ClinVar Variant Classifications

1122 submitted variants in ClinVar

Classification Summary

Pathogenic2
Likely Pathogenic7
VUS658
Likely Benign347
Benign52
Conflicting54
2
Pathogenic
7
Likely Pathogenic
658
VUS
347
Likely Benign
52
Benign
54
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
2
0
0
0
2
Likely Pathogenic
7
0
0
0
7
VUS
52
587
18
1
658
Likely Benign
3
35
31
278
347
Benign
1
11
23
17
52
Conflicting
54
Total65633722961,120

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

26 pathogenic / likely-pathogenic (of 32) ClinVar copy-number / structural variants overlap NEFH — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

NEFH · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →